pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Approval · news · pharmadog
← back to Approval
News · Approval
1,552
stories
Aug 31, 26
Recon: FDA approves Protagonist and Takeda’s drug for rare blood cancer; Lilly to buy Merida for up to $2.88B
raps
Aug 30, 26
STAT+: FDA approves Protagonist and Takeda’s drug for rare blood cancer
stat
Aug 30, 26
STAT+: Alnylam defends heart disease drugs after failure of AstraZeneca’s Wainua
stat
Aug 29, 26
Landmark approval for pancreatic cancer; Reactions to Lilly’s Phase 1 secrecy; and more
endpoints
Aug 28, 26
FDA approves Takeda, Protagonist drug for rare blood disorder
endpoints
Aug 28, 26
FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder
fda press
Aug 28, 26
Juul gets OK to sell updated vaping device with age-gating technology
stat
Aug 28, 26
BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
biospace
Aug 28, 26
Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
biopharma dive
Aug 28, 26
‘Worse than expected’ Wainua data muddies water for TTR silencers
biospace
Aug 28, 26
BioXcel files for bankruptcy, will sell assets to Teva for up to $125M
biospace
Aug 28, 26
Mounjaro scores FDA approval to reduce CV risk; Teva to buy an approved drug
endpoints
Aug 28, 26
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
biopharma dive
Aug 28, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
Aug 28, 26
STAT+: AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching
stat
Aug 28, 26
Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist Mounjaro
biospace
Aug 28, 26
BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test
fiercebiotech
Aug 28, 26
FDA green lights Priovant drug for rare skin disease
biopharma dive
Aug 28, 26
STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and more
stat
Aug 28, 26
Priovant nabs first FDA approval for targeted tablet in dermatomyositis
biospace
Aug 28, 26
STAT+: Cytokinetics details trial win for what could be its next approval
stat
Aug 28, 26
#ESC26: Data in hand, Cytokinetics looks to expanded Myqorzo approval
endpoints
Aug 28, 26
Teva saddles up as stalking horse bidder for bankrupt BioXcel’s neuroscience portfolio
fiercebiotech
Aug 28, 26
Opinion: We quit the CDC last year. The problems we protested remain
stat
Aug 28, 26
FDA issues untitled letter to Alar for false advertising of investigational drug
raps
Aug 27, 26
Gilead gets another HIV treatment approval, extending lenacapavir's dominance
endpoints
Aug 27, 26
Roivant's dermatomyositis drug Lisraya snags FDA approval
endpoints
Aug 27, 26
STAT+: FDA approves Roivant therapy for rare autoimmune disease
stat
Aug 27, 26
FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults
fda press
Aug 27, 26
New data could widen use of AstraZeneca, Amgen immune disease drug
biopharma dive
← prev
page 27 of 52
next →